Combining FAK inhibitors with Janus kinase/STAT3 inhibition has yielded significant tumor growth inhibition and increased survival across multiple PDAC mouse models, highlighting the potential of dual stromal and tumor-targeting therapies [51]. Here, STAT3 is linked to neoplasm.